STIM

+ Watchlist + Portfolio

Neuronetics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.14
52-Week Range: $0.80 – $3.71
Market Cap: $235.45M
P/E (TTM): —
EPS (TTM): -0.42
Dividend Yield: —

Advanced Metrics

Price/Book: 13.21
PEG Ratio: —
Return on Equity: -116.10%
Return on Assets: -10.55%
Gross Margin: 49.38%
Operating Margin: -3.61%
Profit Margin: -19.62%
Current Ratio: 1.88
Debt/Equity: 4.00
Total Debt: $86.52M
Free Cash Flow: $345.63K
Revenue Growth: 9.10%
Earnings Growth: —
Enterprise Value: $306.57M

STIM Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$65.21M	$71.35M	$74.89M	$149.16M
Cost of Revenue	$15.48M	$19.64M	$20.73M	$76.85M
Gross Profit	$49.72M	$51.70M	$54.16M	$72.31M
Research & Development	$9.34M	$9.52M	$12.77M	$6.58M
Selling, General & Admin	$75.50M	$72.74M	$75.95M	$97.16M
Operating Expenses	$84.83M	$82.26M	$88.72M	$103.74M
Operating Income	-$35.11M	-$30.55M	-$34.56M	-$31.44M
EBITDA	-$31.96M	-$23.36M	-$35.17M	-$28.05M
Pretax Income	-$37.21M	-$30.16M	-$43.74M	-$39.12M
Net Income	-$37.16M	-$30.19M	-$43.71M	-$39.00M
Diluted EPS	-1.38	-1.05	-1.37	-0.59
Diluted Shares	26.90M	28.66M	31.63M	65.95M

STIM Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$70.34M	$59.68M	$18.46M	$28.13M
Receivables	$13.82M	$17.84M	$24.29M	$16.89M
Inventory	$8.90M	$8.09M	$4.25M	$4.33M
Current Assets	$98.77M	$93.79M	$58.12M	$61.55M
Total Assets	$116.88M	$115.83M	$140.90M	$141.55M
Current Liabilities	$33.20M	$19.81M	$31.27M	$30.52M
Long-Term Debt	$22.83M	$59.28M	$55.15M	$65.81M
Total Debt	$39.74M	$62.47M	$82.63M	$90.30M
Total Liabilities	$59.82M	$81.64M	$109.10M	$115.31M
Retained Earnings	-$345.89M	-$376.08M	-$419.79M	-$458.79M
Shareholders' Equity	$57.06M	$34.19M	$27.71M	$22.38M
Working Capital	$65.57M	$73.98M	$26.86M	$31.03M
Net Debt	—	—	$36.69M	$37.67M

STIM Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$30.74M	-$32.04M	-$31.00M	-$20.37M
Capital Expenditure	-$3.27M	-$2.37M	-$1.47M	-$801.00K
Free Cash Flow	-$34.01M	-$34.41M	-$32.46M	-$21.18M
Depreciation & Amortisation	$1.65M	$2.01M	$2.07M	$3.46M
Stock-Based Compensation	$8.75M	$7.32M	$5.60M	$6.85M
Investing Cash Flow	$6.73M	-$1.32M	-$2.41M	-$801.00K
Financing Cash Flow	$207.00K	$22.70M	-$6.81M	$35.85M
Share Repurchases	—	$0.00	$0.00	-$1.73M
Net Change in Cash	-$23.80M	-$10.66M	-$40.22M	$14.68M

STIM Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$31.98M	$38.11M	$37.30M	$41.78M	$34.45M
Cost of Revenue	$16.24M	$20.35M	$20.19M	$20.07M	$18.30M
Gross Profit	$15.74M	$17.76M	$17.11M	$21.70M	$16.15M
Research & Development	$1.62M	$1.80M	$1.50M	$1.67M	$1.36M
Selling, General & Admin	$25.14M	$24.02M	$22.93M	$25.08M	$23.79M
Operating Expenses	$26.75M	$25.82M	$24.43M	$26.75M	$25.15M
Operating Income	-$11.01M	-$8.06M	-$7.32M	-$5.04M	-$8.99M
EBITDA	-$10.06M	-$7.17M	-$6.51M	-$4.32M	-$8.07M
Pretax Income	-$12.67M	-$9.87M	-$9.39M	-$7.19M	-$10.81M
Net Income	-$12.68M	-$10.12M	-$9.04M	-$7.16M	-$10.79M
Diluted EPS	-0.21	-0.15	-0.13	-0.10	-0.16
Diluted Shares	61.47M	66.18M	67.31M	68.76M	69.59M

STIM Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$20.22M	$10.97M	$27.97M	$28.13M	$13.21M
Receivables	$26.89M	$26.64M	$19.19M	$16.89M	$16.21M
Inventory	$4.07M	$4.94M	$4.32M	$4.33M	$4.71M
Current Assets	$60.67M	$56.14M	$64.89M	$61.55M	$47.17M
Total Assets	$141.99M	$134.65M	$145.47M	$141.55M	$125.44M
Current Liabilities	$24.84M	$27.80M	$28.94M	$30.52M	$28.29M
Long-Term Debt	$55.34M	$55.54M	$65.67M	$65.81M	$61.30M
Total Debt	$82.54M	$80.66M	$90.75M	$90.30M	$85.39M
Total Liabilities	$102.46M	$103.14M	$114.11M	$115.31M	$108.38M
Retained Earnings	-$432.46M	-$442.58M	-$451.63M	-$458.79M	-$469.58M
Shareholders' Equity	$35.45M	$27.15M	$27.36M	$22.38M	$13.27M
Working Capital	$35.83M	$28.34M	$35.95M	$31.03M	$18.89M
Net Debt	$35.12M	$44.57M	$37.70M	$37.67M	$48.08M

STIM Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$16.99M	-$3.50M	-$785.00K	$908.00K	-$9.42M
Capital Expenditure	-$219.00K	-$252.00K	-$114.00K	-$216.00K	-$197.00K
Free Cash Flow	-$17.21M	-$3.76M	-$899.00K	$692.00K	-$9.62M
Depreciation & Amortisation	$911.00K	$901.00K	$886.00K	$767.00K	$745.00K
Stock-Based Compensation	$1.44M	$1.81M	$1.41M	$2.18M	$1.68M
Investing Cash Flow	-$219.00K	-$252.00K	-$114.00K	-$216.00K	-$172.00K
Financing Cash Flow	$18.98M	$1.00K	$17.90M	-$1.03M	-$5.58M
Net Change in Cash	$1.76M	-$3.75M	$17.00M	-$337.00K	-$15.17M

Market Snapshot

About

Neuronetics, Inc. is a commercial-stage medical technology company focused on non-invasive treatments for psychiatric disorders. The company develops and markets the NeuroStar Advanced Therapy system, a transcranial magnetic stimulation device for treating major depressive disorder and other mental health conditions.